United Therapeutics (UTHR) Interest & Investment Income (2009 - 2026)

United Therapeutics (UTHR) has 16 years of Interest & Investment Income data on file, last reported at $41.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 18.2% year-over-year to $41.8 million; the trailing twelve-month figure through Mar 2026 stood at $182.7 million (down 6.98% YoY), and the FY2025 full-year result was $192.0 million, down 3.57% from the prior year.
• Interest & Investment Income declined to $41.8 million in Q1 2026, from $43.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $53.8 million in Q1 2024 to a low of $4.3 million in Q1 2022.
• A 5-year average of $37.7 million and a median of $45.3 million in 2023 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income soared 579.07% in 2023 and retreated 18.2% in 2026, its largest moves.
• Tracing UTHR's Interest & Investment Income over 5 years: stood at $20.8 million in 2022, then jumped by 145.19% to $51.0 million in 2023, then slipped by 3.33% to $49.3 million in 2024, then retreated by 12.37% to $43.2 million in 2025, then retreated by 3.24% to $41.8 million in 2026.
• Business Quant data shows UTHR's Interest & Investment Income at $41.8 million in Q1 2026, $43.2 million in Q4 2025, and $46.4 million in Q3 2025.